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Abstract
Background: Hereditary hemorrhagic telangiectasia (HHT) is a rare vascular disease with autosomal dominant
inheritance. Disease-causing variants in endoglin (ENG) and activin A receptor type II-like 1 (ACVRL1) genes are
detected in more than 90% of cases submitted to molecular diagnosis.
Methods: We used data from the RiHHTa (Computerized Registry of Hereditary Hemorrhagic Telangiectasia) registry
to describe genetic variants and to assess their genotype-phenotype correlation among HHT patients in Spain.
Results: By May 2019, 215 patients were included in the RiHHTa registry with a mean age of 52.5 ± 16.5 years and
136 (63.3%) were women. Definitive HHT diagnosis defined by the Curaçao criteria were met by 172 (80%) patients.
Among 113 patients with genetic test, 77 (68.1%) showed a genetic variant in ACVRL1 and 36 (31.8%) in ENG gene.
The identified genetic variants in ACVRL1 and ENG genes and their clinical significance are provided. ACVRL1
mutations were more frequently nonsense (50%) while ENG mutations were more frequently, frameshift (39.1%).
ENG patients were significantly younger at diagnosis (36.9 vs 45.7 years) and had pulmonary arteriovenous
malformations (AVMs) (71.4% vs 24.4%) and cerebral AVMs (17.6% vs 2%) more often than patients with ACVRL1
variants. Patients with ACVRL1 variants had a higher cardiac index (2.62 vs 3.46), higher levels of hepatic functional
blood tests, and anemia (28.5% vs 56.7%) more often than ENG patients.
Conclusions: ACVRL1 variants are more frequent than ENG in Spain. ACVRL1 patients developed symptomatic liver
disease and anemia more often than ENG patients. Compared to ACVRL1, those with ENG variants are younger at
diagnosis and show pulmonary and cerebral AVMs more frequently.
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Introduction
Hereditary hemorrhagic telangiectasia (HHT) or Rendu-
Osler-Weber syndrome (ORPHA774; HHT 1: OMIM#
187300; HHT 2: OMIM# 600376) is a rare autosomal-
dominant multisystemic vascular disease characterized
by telangiectasia and larger vascular malformations
(VMs), with a prevalence of 1 in 6000 [1–4]. Although
more than 800 pathogenic variants in more than 5 genes
have been reported, disease-causing variants in endoglin
(ENG; chromosome 9q) and activin A receptor type II-
like 1 (ACVRL1; chromosome 12q) genes are detected in
more than 90% of cases submitted to molecular diagno-
sis and cause HHT1 and HHT2, respectively [5–7].
Mutations in SMAD4 (encoding the transcription factor
Smad4) have been described in less than 2% of the HHT
population and cause juvenile polyposis/HHT overlap
syndrome [8]. Endoglin (encoded by ENG) is an auxiliary
co-receptor at the endothelial cell surface that promotes
BMP9 signaling through the activin receptor-like kinase
1 (ALK1; encoded by ACVRL1). Both proteins contribute
to the signaling hub formed by BMP9-Endoglin-ALK1-
Smad with a high impact in angiogenesis [9–11].
HHT can be diagnosed either through molecular genetic
testing or using the Curaçao clinical criteria (recurrent epi-
staxis, cutaneous/mucosal telangiectasia, visceral involvement
and a first-degree relativewith HHT) [4, 5, 7, 12]. However,
since HHT is an age-dependent disease, genetic study is a
very useful tool for diagnosis in young patients [4, 5, 7].
Telangiectasia is the characteristic lesion in HHT and shows
dilated postcapillary venules directly connected with dilated
arterioles losing the capillary bed [7, 13]. Telangiectasia in
nasal mucosae causes spontaneous and recurrent epistaxis
that are the most common and usually the earliest clinical
manifestation of HHT [7, 12, 14]. Although endoglin and
ALK1 are components of the same BMP9 receptor complex,
they are structurally and functionally different proteins. Thus,
pathogenic variants in their genes are related to different
clinical phenotypes [5, 9]. Pulmonary arteriovenous malfor-
mations (AVMs) and brain VMs are more common in
patients with HHT1, while vascular hepatic malformations
are more frequent in HHT2 [4, 7, 15].
Of note, there is high inter-familial as well as intra-
familial vascular involvement and clinical manifestations
variability [7, 16]. Therefore, genetic study is essential
for diagnostic confirmation and also for relatives’ genetic
screening [5, 7, 17]. This low prevalence and clinical
variability makes HHT understanding challenging, espe-
cially in uncommon situations [18]. Development of
registries that include clinical and genetic data may help
to overcome these difficulties, and represent a priority in
the management of rare diseases [19, 20]. The use of
quality registries reflects patients’ management in standard
clinical practice, helps reaching a consensus on diagnostic-
therapeutic measures and also generates hypotheses for
developing clinical trials [19–21]. The aim of the present
study is to describe the genetic variants and their clinical
correlation in HHT patients from the RiHHTa (Computer-
ized Registry of Hereditary Hemorrhagic Telangiectasia)
registry, comprehending a cohort of individuals followed-
up at specialized HHT centers in Spain [14].
Material and methods
Study design
RiHHTa is a multicenter, prospective and observational
registry, developed within the Rare Diseases Working
Group of the Spanish Society of Internal Medicine.
RiHHTa registry is currently formed by 42 researchers
from 29 Spanish hospitals. RiHHTa has an online design
(accessible from https://rihhta.healthincode.com) avail-
able in Spanish or English with individual encoded
access for each researcher. The rationale and method-
ology of RiHHTa have been published elsewhere [14].
Patients’ personal data included in the registry are in
agree with Spanish personal data law (Ley 15/1999 de
Protección de Datos de Carácter Personal). To safeguard
the identity of the included patients, the RiHHTa regis-
try generate an encrypted identifier for each patient. All
patients (or their relatives) provided written consent for
participation in the registry. The design of the RiHHTa
registry was approved by the Ethics Committee of the
Hospital Universitari de Bellvitge (Barcelona, Spain; ethic
approval number PR241/16). The creation of RiHHTa
counted on the nonremunerated collaboration of the
genetic studies company Health in Code (A Coruña,
Spain), which has broad experience in cardiomyopathy
registries [22].
The main objective of the present study was to describe
the type of genetic variants identified in HHT patients
included in RiHHTa registry and to analyse the genotype-
phenotype correlation according to these mutations in
ENG or ACVRL1 genes.
Patient and variables
Patients included in the RiHHTa registry with a “defin-
ite” clinical diagnosis according to the Curaçao Criteria
(≥ 3 criteria) or with a genetic diagnosis were considered
for this study [12]. The inclusion period was from June
2016 to June 2019. Demographic data, clinical character-
istics and complementary tests were collected according
to mutations in ENG or ACVRL1 genes. The severity of
nosebleeds was measured according to the epistaxis
severity score (ESS). ESS is an on-line tool that estimates
the severity of epistaxis according to clinical data occur-
ring during the last 3 months. Epistaxis is considered
moderate or severe if ESS results > 4 or > 7 points,
respectively [23].
For the screening of pulmonary visceral involve-
ment, a contrast transthoracic echocardiography
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(TTE) was performed to establish the degree of
right-left shunt (R-L) and the need to undergo a thoracic
computed tomography (CT) angiography to objectively
confirm the presence of pulmonary arteriovenous malfor-
mations (AVM) [7, 24]. In addition, an abdominal CT
angiography, magnetic resonance imaging (MRI) or dop-
pler ultrasound were performed to study hepatic and/or
abdominal VMs. Hepatic involvement was defined accord-
ing to the three classical patterns of abnormal vascular
communications: arteriovenous shunt (from hepatic artery
to hepatic vein), portovenous shunt (from portal vein to
hepatic vein) and arterioportal shunt (from hepatic artery
to portal vein) [25]. Neurological involvement studies
were carried out when neurological symptoms or family
history, by a cerebral CT and/or MRI. An endoscopic
digestive study was performed when there was dispropor-
tionate anaemia to the degree of epistaxis or objectively
confirmed overt gastrointestinal (GI) bleeding [7].
Molecular analysis
All included patients underwent genetic testing. The se-
quencing technique depended on each treating centers’
preference. Because RiHHTa includes patients from all
around Spain, different genetic techniques have been used
in the included patients. These techniques include Next
generation sequencing (NGS) technologies, Sanger sequen-
cing and other techniques such Multiplex ligation-
dependent probe amplification (MLPA). In patients in
which NGS was used, coding exons and intronic boundar-
ies of 9 genes related to HHT disease or HHT-like pheno-
types (ACVRL1, BMP10, BMPR1A, BMPR2, ENG, GDF2,
RASA1, SMAD1, SMAD4) were captured using a custom
probe library (SureSelect Target Enrichment Kit for Illu-
mina paired-end multiplexed sequencing method; Agilent
Technologies, Santa Clara, California, USA), and se-
quenced on the HiSeq 1500 platform following Illumina
protocols. To determine the pathogenicity of the included
variants in the RiHHTa registry, all mutations were
checked again by Health in Code SL (A Coruña, Spain)
and labeled according to the American College of Medical
Genetics and Genomics (ACMG) guidelines [26]. When-
ever a genetic variant was identified through NGS, Sanger
sequencing was the preferred used method for familial
evaluation, unless technically not feasible.
Statistical analysis
A descriptive statistical analysis was performed for all
categorical and continuous variables and expressed as
proportions or means with standard deviations (SD), re-
spectively. The descriptive analysis was performed for
the entire sample. We used chi-square or Fisher’s exact
test to compare categorical data between groups; Fisher’s
exact test has been used when expected frequencies were
less than 5. Continuous variables were compared using
Student t-test. We used two-tailed unpaired t-tests to
compare normally distributed continuous data between
two groups, and we used the Mann-Whitney U test for
non-normally distributed continuous data comparisons.
Normality was assessed using Shapiro-Wilk test. P values
of < 0.05 were considered statistically significant. Ana-
lyses were performed using SPSS, version 18 for the PC
(SPSS, Inc. Chicago, IL, USA).
Results
Baseline characteristics
During the study period, 215 patients from 29 Spanish
hospitals were included in the RiHHTa registry, 136
(63.3%) were women. Mean age at time of inclusion of
52.5 ± 16.5 years old. Most (88.4%) patients were Cauca-
sian. The mean age at diagnosis of HHT was 42.2 ± 17.5
years old. Epistaxis was the most frequent symptom at
disease onset which allowed the diagnosis of suspicion
in 197 (91.6%) patients, while in another 7 (3.2%)
patients the diagnosis arose after a central nervous sys-
tem event (including brain abscess in 4 (1.9%) patients,
and stroke, in 3 (1.4%). Family history were present in
178 (82.8%) patients and in 167 (77.7%), muco-
cutaneous telangiectasia were observed at diagnosis or
during the follow-up. Definite HHT diagnosis defined by
the Curaçao criteria were met by 172 (80%) patients,
while the remaining were diagnosed through a positive
genetic test, after a thorough familial evaluation. .
Epistaxis was also the most frequent symptom at diag-
nosis of HHT with a mean ESS of 3.65 ± 2.5. Anemia
was present in 92 (42.8%) patients, 12 (5%) patients had
a history of previous venous thromboembolic disease
and 8 (3.7%) patients had atrial fibrillation. Medical at-
tention because of epistaxis at Emergency Department
during follow-up was required by 69 (32.1%) patients
and red blood cell transfusion by 38 (17.7%) patients.
Pulmonary AVMs were detected in 48 (22.3%) patients
and liver VMs identified by imaging test (CT angiog-
raphy, MRI or doppler ultrasound) were observed in 58
(27%) patients. Pancreatic involvement was detected in
seven (3.3%) subjects and other abdominal VMs in 16
(7.4%) patients, including splenic, renal and gastro-
omental arterial aneurysms. Brain malformations were
reported in five patients (2.3%) and GI telangiectasia
were observed in 26 (12.1%) patients (Table 1).
Types of pathogenic variants
A genetic test was performed in 113 HHT patients from
the RiHHTa registry (Table 2). For the mutation ana-
lysis, Sanger sequencing was performed in 65 (57.5%)
cases, NGS in 38 (33.6%) and other techniques, such as
MLPA, in 10 (8.8%) cases. A genetic variant was identi-
fied in ACVRL1 gene in 77 (68.1%) patients, whereas 36
(31.8%) patients harboured a genetic variant in ENG
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gene. According to the type of mutation, ACVRL1 patients
presented more frequently nonsense mutations (50.6%),
while in ENG patients the most frequent type was frame-
shift (36.1%). Supplementary Table 1 shows those 52 vari-
ants we have complete genetic data, as well as their
frequencies in gnomAD and the bioinformatic predictor’s
evaluation. Supplementary Table 2 shows the ACMG clas-
sification of these variants. Among these variants, we iden-
tified 17 missense variants in ACVRL1, 41% of them were
localized in the kinase domains of exons 7 and 8, and 29%
in exon 3. However, missense variants in ENG gene were
dispersed among the extracellular domain of the protein.
In both genes, the predominant variants were the ones
that caused loss-of-function mechanism (nonsense, frame-
shift and splice-site), which would almost certainly be
pathogenic in these genes. Figure 1 shows a schematic
representation of ACVRL1 and ENG, as well as the exonic
variants identified.
Genotype-phenotype correlation
There were no significant differences between ENG and
ACVRL1 patients in the age of inclusion, gender, num-
ber of Curaçao criteria, recurrent epistaxis, ESS, muco-
cutaneous telangiectasia, family history, hepatic VMs or
GI involvement.
Compared to patients with ACVRL1 mutations, ENG
patients were significantly younger at diagnosis (36.9 vs
45.7 years) and usually had more pulmonary AVMs (71.4
vs 24.4%), as well as cerebral AVMs (17.6% vs 2%).
Those with ACVRL1 mutation had a higher cardiac
index (3.46 L/min/m2 vs 2.62 L/min/m2), higher levels of
hepatic functional blood tests and more frequently
anemia (56.7% vs 28.5%) than ENG patients (Table 3).
Discussion
The present study using data from the RiHHTa registry
represents the largest series about genetic variants of
HHT patients in Spain. A previous study reported 74
Table 1 Baseline characteristics










No clinical data 14 (6.5)
Underlying conditions, n (%)
Current smoker 26 (12.1)
Hypertension 43 (20)
Diabetes Mellitus 11 (5.1)
Dyslipidemia 33 (15.3)
Venous Thromboembolism 12 (5.5)
Atrial fibrillation 8 (3.7)
HHT criteria, n (%)
4 HHT criteria 99 (46)
3 HHT criteria 73 (34)
2 or less HHT criteria 32 (14.9)




No clinical data 26 (12.1)
Symptoms at onset, n (%)
Nosebleeds 197 (91.6)
Central Nervous system event 7 (3.2)
Cerebral abscess 4 (1.9)
Stroke 3 (1.4)
Cutaneous telangiectases 1 (0.5)
Dyspnea 1 (0.5)
Anemia 1 (0.5)
No clinical data 8 (3.7)
Muco-cutaneous telangiectasia, n (%) 167 (77.7)
Baseline ESS 3.65 (2.5)
Gene mutation, n (%)
ENG 36 (16.7)
ACVRL1 77 (35.8)
No clinical data 102 (47.2)
Visceral involvement, n (%)
Pulmonary AVM 48 (22.3)
Cerebral AVM 5 (2.3)
Hepatic involvement 58 (27)
Gastrointestinal involvementa 26 (12.1)
HHT Hereditary hemorrhagic telangiectasia, SD Standard deviation, ESS Epistaxis
Severity Score, AVM Arteriovenous malformation
aGastrointestinal involvement detected by fibrogastroscopy and / or colonoscopy
Table 2 Summary of the variants analysis
GENE mutation ENG, n (%) ACVRL1, n (%)
Patients, n 36 77
Sequencing method, n (%)
Sanger 20 (55.5) 45 (58.4)
NGS 12 (33.3) 26 (33.8)
Others 4 (11.1) 6 (7.8)
Variant type, n (%)
Nonsense 10 (27.7) 39 (50.6)
Frameshift 13 (36.1) 20 (25.9)
Splice-site 4 (11.1) 3 (3.9)
Missense 9 (25) 15 (19.4)
NGS Next-generation sequencing
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clinically diagnosed Spanish patients, most of them with
ACVRL1 variants [27]. In our cohort, 77 out of 113
(68.1%) patients also had variants in the ACVRL1 gene.
This finding is in agreement with previous data from
other Mediterranean countries but different to Northern
Europe or North America, where pathogenetic variants
in ENG are more frequent than in ACVRL1 [28, 29].
We have observed that patients with ENG gene vari-
ants were diagnosed at a younger age. This finding could
be influenced because oral and nasal mucosal telangiec-
tases are present earlier in life in patients with HHT1
than with HHT2, so epistaxis also start earlier in these
patients [30]. According to previous studies, we have ob-
served a higher prevalence of pulmonary AVMs and
cerebral VMs in patients with ENG mutations than in
those with ACVRL1 mutations (5–29%) [20, 23, 27, 31].
Hepatic involvement has been described more com-
monly among ACVRL1 patients, with a wide range of
prevalence from 8 to 78% [29, 30, 32, 33]. In our series,
though vascular hepatic involvement was more frequent
in ACVRL1 patients, no statistically significant differences
were detected between ENG and ACVRL1 patients, prob-
ably because different screening methods were used by
RiHHTa investigators. However, patients with ACVRL1
mutation had a higher CI and levels of hepatic functional
blood tests than ENG patients, suggesting a more severe
hepatic involvement in patients with ACVRL1 mutations.
In fact, in two studies including patients with genotype
data available, those who developed symptomatic liver
disease had ACVRL1 mutation [15, 34].
In our study, there were no statistically significant dif-
ferences in the presence of GI telangiectasia between
ENG and ACVRL1 patients. Canzonieri et al. and van
Tuyl et al. systemically studied the extent of GI involve-
ment with gastroscopy, video capsule endoscopy, and
colonoscopy in 22 and 35 HHT patients, respectively,
and found a higher prevalence of telangiectasia in pa-
tients with ENG mutation [8, 35, 36]. In a recent study,
Mora-Luján et al. reported that age, tobacco use, ENG
mutation, and hemoglobin levels were associated with
GI involvement in HHT comparing 67 patients with GI
disease and 28 with negative GI study [37]. However,
Berg et al., Sabbà et al. and Letteboer et al. assessing
genotype-phenotype relationship in HHT patients, re-
ported a similar incidence of GI telangiectasia in HHT1
and HHT2 patients [38–40].
Similar to previous studies, the most frequent type of
pathogenic variants we have identified in both ENG and
ACVRL1 genes were those predicted to cause a loss-of-
function (nonsense, frameshift and splice-site) [19, 24].
Missense variants in ACVRL1 gene were predominantly
localized in the kinase domains of exons 7 and 8, while
missense variants in ENG gene were dispersed in the extra-
cellular domain of the protein [27]. In a study conducted by
Sabbà et al., the correlation between phenotype and variant
type was analysed in a cohort of 77 HHT2 patients.
ACVRL1 patients were divided into three subgroups
according to the type mutation: truncating mutations (20
patients), missense mutations (47 patients) and the c.626-
3C >G splicing mutation (10 patients). Patients with c.626-
Fig. 1 Schematic representation of the exons (boxes) of ACVRL1 and ENG genes. The identified exonic variants in our cohort are presented
according to their location (colored boxes represent specific functional domains, each one of them is explained in the legends)
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3C >G mutation had a higher prevalence of pulmonary
AVMs than the other two subgroups [29]. This data could
be of interest for the evaluation of variants of uncertain
significance and for defining useful prediction criteria based
on the type of mutation. Genetic study, including the
description of new pathogenic variants, usually avoid un-
necessary complementary tests, especially in patients with
no family history or those who meet less than 3 Curaçao
criteria, as young patients [4, 5, 7, 33]. In fact, genetic study
has been found preferable to the clinical Curaçao criteria
among patients between 0 and 21 years [41].
Our study has some limitations and strengths that
should be mentioned. First, it is an observational study
from RiHHTa database. Thus, some non-measured vari-
ables could lead to a possible bias. Second, genetic and
screening tests varied with local practice. Third, a variety
of clinicians entered data into the registry, which may
lend itself to potential inaccuracies in the data being re-
ported. However the information obtained through
RiHHTa registry is valuable and allows thorough under-
standing the natural history of HHT. Moreover, patients
in the RiHHTa registry were from different centers in
Spain, which can better reflect epidemiology data of the
disease in this country.
Table 3 Genotype-phenotype correlation in ENG and ACVRL1
patients
GENE Mutation ENG ACVRL1 p-value
Patients, n 36 77
Sex, n (%)
Male 13 (36) 23 (29.9) 0.507
Female 23 (64) 54 (70.1)
Age at diagnosis (years),
mean ± SD
36.9 ± 17.9 45.7 ± 16.8 0.036
Ethnicity, n (%)
Caucasian 36 (100) 67 (87) 0.218
Hispanic 0 (0) 5 (6.5)
Others/unknown 0 (0) 5 (6.5)
Hypertension, n (%) 8 (22.2) 23 (29.9) 0.133
Diabetes Mellitus, n (%) 1 (2.7) 9 (11.7) 0.146
Dyslipidaemia, n (%) 7 (19.4) 22 (28.5) 0.561
Venous Thromboembolism,
n(%)
4 (11.1) 4 (5.2) 0.269
Atrial fibrillation, n (%) 2 (5.5) 6 (7.8) 0.588
HHT criteria, n (%) 0.130
4 HHT criteria 23 (63.8) 38 (49.3)
3 HHT criteria 9 (25) 27 (35.1)
2 or less HHT criteria 4 (11.1) 12 (15.6)
Family history, n (%)
Positive 34 (94.4) 73 (94.8) 0.626
Negative 1 (2.7) 2 (2.6)
Unknown 1 (2.7) 2 (2.6)
Symptoms at onset, n (%) 0.461
Nosebleeds 32 (88.9) 65 (84.4)
Cerebral abscess 1(2.7) 0 (0)
Others 2 (5.5) 5 (6.5)
No clinical data 1 (2.7) 9 (11.7)
Muco-cutaneous
telangiectasia, n (%)
29 (80.5) 62 (80.5) 0.645
Cerebral abscess, n (%) 2 (5.5) 0 (0) 0.132
ESS basal, mean ± SD 3.45 ± 2.5 3.51 ± 2.3 0.94
Anemia, n (%) 10 (27.7) 38 (49.3) 0.026
Cardiac index (L/min/m2),
mean ± SD
2.62 ± 0.7 3.46 ± 0.79 0.021
Contrast TTE (R-L shunt grade),
n (%)
< 0.005
0 2 (5.5) 28 (36.4)
1 12 (33.3) 17 (22.1)
2 10 (27.7) 4 (5.2)
3 4 (11.1) 3 (3.9)
4 1 (2.7) 0 (0)
Unknown 1 (2.7) 1 (1.3)
Pulmonary AVM, n (%) 20 (55.5) 11 (14.3) < 0.005
Table 3 Genotype-phenotype correlation in ENG and ACVRL1
patients (Continued)
GENE Mutation ENG ACVRL1 p-value
Cerebral AVM, n (%) 3 (8.3) 1 (1.3) < 0.005
Hepatic involvement, n (%) 9 (25) 33 (42.8) 0.075
AV shunt 2 (5.5) 15 (19.4) 0.128
PV shunt 3 (8.3) 2 (2.6) 0.078
AP shunt 1 (2.7) 9 (11.7) 0.385
FNH 0 (0) 2 (2.6) 1
NRH 0 (0) 1 (1.3) 1
Telangiectasia 4 (11.1) 20 (25.9) 0.413
Liver function test (IU/L),
mean ± SD
Aspartate aminotransferase 11.2 ± 10.4 19.7 ± 11.6 0.004
Alanine transaminase 11.5 ± 11.3 19.4 ± 12.5 0.010
Gamma-glutamyl transferase 11.2 ± 12.8 43.4 ± 71.3 0.004
Alkaline phosphatase 35.4 ± 37.1 68.5 ± 69 0.026
Bilirubin 5.61 ± 8.7 5.19 ± 19.7 0.92
Pancreatic involvement,
n (%)
0 (0) 6 (7.8) 0.302
Gastrointestinal
involvement, n (%)
Gastroscopy 8 (22.2) 9 (11.7) 0.603
Colonoscopy 3 (8.3) 3 (3.9) 0.622
AV Arteriovenous (from hepatic artery to hepatic vein), PV Portovenous shunt
(from portal vein to hepatic vein), AP Arterioportal (from hepatic artery to
portal vein). NRH Nodular regenerative hyperplasia, FNH Focal nodular
hyperplasia, SD Standard deviation, R-L Right-left shunt
Sánchez-Martínez et al. Orphanet Journal of Rare Diseases          (2020) 15:138 Page 6 of 8
Conclusions
In conclusion, ACVRL1 variants are most frequent than
ENG variants in Spain. A description of these identified
genetic variants and their clinical significance is pro-
vided. Patients with ACVRL1 variants developed symp-
tomatic liver disease and anemia more usually than ENG
patients. Compared to ACVRL1, those with ENG vari-
ants were younger at diagnosis and show pulmonary and
cerebral AVMs more frequently. The RiHHTa registry
can contribute to improve knowledge and management
of HHT patients.
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